A previous report has indicated that injection of EVs from metabolic syndrome individuals to healthy mice alters and disrupts aorta responses to acetylcholine (Agouni et al., 2011; Safiedeen et al., 2017), activates Fas/Fas ligand signaling pathways, and therefore triggers ROS-dependent activation of neutral sphingomyelinase (Safiedeen et al., 2017). This evidence concerns the gene FAS and metabolic syndrome.